ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 128.94

Change

+1.24 (+0.97)%

Market Cap

USD 28.74B

Volume

0.93M

Average Target Price

USD 159.14 (23.42%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+0.43 (+0.21%)

USD 131.25B
GILD Gilead Sciences Inc.

-0.69 (-0.90%)

USD 98.03B
BIIB Biogen Inc.

-0.38 (-0.11%)

USD 68.13B
CELG Celgene Corporation

N/A

USD 59.28B
SHPG Shire plc

+1.85 (+1.05%)

USD 54.08B
VRTX Vertex Pharmaceuticals Incorpo..

+0.03 (+0.02%)

USD 47.40B
REGN Regeneron Pharmaceuticals Inc.

+0.54 (+0.14%)

USD 43.12B
BMRN BioMarin Pharmaceutical Inc.

+0.06 (+0.06%)

USD 18.84B
INCY Incyte Corporation

+0.13 (+0.20%)

USD 13.83B
GRFS Grifols S.A.

-0.04 (-0.20%)

USD 13.49B

ETFs Containing ALXN

BBH VanEck Vectors Biotech ET.. 5.10 % 0.35 %

+0.17 (+0.14%)

USD 0.45B
FMDG Fieldstone Merlin Dynamic.. 4.68 % 0.80 %

N/A

N/A
IBB iShares Nasdaq Biotechnol.. 3.75 % 0.47 %

-0.06 (-0.05%)

USD 9.22B
RYH Invesco S&P 500 Equal Wei.. 1.79 % 0.40 %

+0.89 (+0.45%)

USD 0.74B
QQXT First Trust NASDAQ-100 Ex.. 1.76 % 0.60 %

-0.07 (-0.14%)

USD 0.09B
ZUH:CA BMO Equal Weight US Healt.. 1.75 % 0.39 %

+0.17 (+0.31%)

CAD 0.40B
XBI SPDR Series Trust S&P Bio.. 1.48 % 0.35 %

-0.15 (-0.17%)

USD 5.20B
SPHB Invesco S&P 500 High Beta 1.25 % 0.25 %

-0.01 (-0.02%)

USD 0.15B
QQQE Direxion NASDAQ-100 Equal.. 1.14 % 0.35 %

-0.04 (-0.09%)

USD 0.19B
QQEW First Trust NASDAQ-100 Eq.. 1.12 % 0.60 %

-0.07 (-0.12%)

USD 0.54B
BTAL AGFiQ U.S. Market Neutral.. 0.49 % 0.00 %

-0.17 (-0.82%)

USD 0.01B
MOM AGFiQ U.S. Market Neutral.. 0.47 % 1.88 %

-0.14 (-0.57%)

USD 6.10M
BLES Inspire Global Hope 0.37 % 0.65 %

-0.08 (-0.30%)

USD 0.09B
RSP Invesco S&P 500 Equal Wei.. 0.24 % 0.20 %

-0.21 (-0.20%)

USD 15.49B
DWPP First Trust Dorsey Wright.. 0.23 % 0.60 %

-0.06 (-0.21%)

USD 0.04B
EUSA iShares MSCI USA Equal We.. 0.19 % 0.15 %

-0.15 (-0.27%)

USD 0.19B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.82% 67% D+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.82% 66% D 67% D+
Trailing 12 Months  
Capital Gain -9.93% 56% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.93% 55% F 34% F
Trailing 5 Years  
Capital Gain 16.38% 63% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.38% 62% D- 42% F
Average Annual (5 Year Horizon)  
Capital Gain -3.34% 38% F 24% F
Dividend Return -3.34% 37% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.16% 87% B+ 61% D-
Risk Adjusted Return -15.77% 36% F 21% F
Market Capitalization 26.24B 98% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -293.05 100% A+ 99% A+
Price/Book Ratio 3.15 58% F 36% F
Price / Cash Flow Ratio 14.92 2% F 5% F
Price/Free Cash Flow Ratio 165.31 1% F 3% F
Management Effectiveness  
Return on Equity -1.12% 82% B- 41% F
Return on Invested Capital 8.70% 86% B 67% D+
Return on Assets -0.73% 90% A- 44% F
Debt to Equity Ratio 34.50% 38% F 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 128.94

Change

+1.24 (+0.97)%

Market Cap

USD 28.74B

Volume

0.93M

Average Target Price

USD 159.14 (23.42%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-10-17